GL1X · GenesisL1 explorer

MolNFT v1 · #62266 · protein

Structure of inhibited human enos oxygenase domain

3EAH · Nitric oxide synthase, endothelial: “Structure of inhibited human enos oxygenase domain”. X-ray diffraction, 4 ligands (HEC, 327, ZN), 8 pockets (best druggability 0.85). MolNFT v1 #62266 on GenesisL1: 3D structure, binding sites…

PDB
3EAH
Type
protein
Length
800 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Nitric oxide synthase, endothelial
EC
1.14.13.39
UniProt
P29474
Ligands
HEC, 327, ZN, CL
Pockets
8 · best druggability 0.85

Structure

x-ray diffraction · 2 distinct chains · 41% helix, 16% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ANitric oxide synthase, endothelial (EC 1.14.13.39)protein39941% helix, 17% strandP29474
BNitric oxide synthase, endothelial (EC 1.14.13.39)protein40140% helix, 15% strandP29474

Ligands and binding sites

  • HEC · Heme C · ligand · 2 copies · chains A, B
  • 327 · (3S,5E)-3-propyl-3,4-dihydrothieno[2,3-f][1,4]oxazepin-5(2H)-imine · ligand · 2 copies · chains A, B
  • ZN · Zinc ion · metal · chains A, B
  • CL · Chloride ion · ion · 2 copies · chains A, B
  • MPD · (4S)-2-methyl-2,4-pentanediol · additive · 4 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

8 pockets found on a 1 Å grid, 4 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
111590.850.86113HEC, 327, CL, MPD
210760.830.8476MPD, CL, HEC, 327
31090.540.8318empty
4860.510.8319empty
5870.330.7414empty

Interfaces

1 interface between chains.

  • A–B · 2610 Ų buried · 34 hydrogen bonds · protein-protein

Compared structures

  • 3EAH · Structure of inhibited human eNOS oxygenase domain · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.